1. Home
  2. LC vs GYRE Comparison

LC vs GYRE Comparison

Compare LC & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LC
  • GYRE
  • Stock Information
  • Founded
  • LC 2006
  • GYRE 2002
  • Country
  • LC United States
  • GYRE United States
  • Employees
  • LC N/A
  • GYRE N/A
  • Industry
  • LC Finance: Consumer Services
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • LC Finance
  • GYRE Health Care
  • Exchange
  • LC Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • LC 1.0B
  • GYRE 897.1M
  • IPO Year
  • LC 2014
  • GYRE N/A
  • Fundamental
  • Price
  • LC $11.00
  • GYRE $8.07
  • Analyst Decision
  • LC Strong Buy
  • GYRE
  • Analyst Count
  • LC 7
  • GYRE 0
  • Target Price
  • LC $16.29
  • GYRE N/A
  • AVG Volume (30 Days)
  • LC 1.1M
  • GYRE 412.5K
  • Earning Date
  • LC 07-29-2025
  • GYRE 08-12-2025
  • Dividend Yield
  • LC N/A
  • GYRE N/A
  • EPS Growth
  • LC 28.90
  • GYRE N/A
  • EPS
  • LC 0.44
  • GYRE 0.02
  • Revenue
  • LC $1,195,590,000.00
  • GYRE $100,643,000.00
  • Revenue This Year
  • LC N/A
  • GYRE $21.04
  • Revenue Next Year
  • LC $18.87
  • GYRE $89.64
  • P/E Ratio
  • LC $25.13
  • GYRE $100.77
  • Revenue Growth
  • LC 8.77
  • GYRE N/A
  • 52 Week Low
  • LC $7.81
  • GYRE $6.11
  • 52 Week High
  • LC $18.75
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • LC 56.11
  • GYRE 43.87
  • Support Level
  • LC $10.42
  • GYRE $7.99
  • Resistance Level
  • LC $11.45
  • GYRE $8.55
  • Average True Range (ATR)
  • LC 0.37
  • GYRE 0.64
  • MACD
  • LC 0.07
  • GYRE -0.05
  • Stochastic Oscillator
  • LC 73.05
  • GYRE 28.82

About LC LendingClub Corporation

LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility. It offers investors access to an asset class that has generally been closed to many investors and only available on a limited basis to institutional investors. The company through the platform offers loan products such as personal, education and patient finance, small business, and auto to interested investors. It generates a majority of the revenue from the transaction fees received from the platform's role in accepting and decisioning applications on behalf of the bank partners to enable loan originations.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: